https://www.selleckchem.com/pr....oducts/rituximab.htm
The difference between the groups in change from baseline was - 2.15 points (95% confidence interval, - 3.07 to - 1.23; p 0.0001; effect size 0.531) after 36 weeks of treatment. Treatment-emergent adverse event incidence was comparable between active treatment and placebo (73.9%, 75.4%). Two deaths determined to be unrelated to drug effects occurred in the GV-971 group. GV-971 demonstrated significant efficacy in improving cognition with sustained improvement across all observation periods of a 36-week trial. GV-971 was safe and
Like
Comment
Share
